

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	ICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/624,946	07	/25/2000	Mark I. Greene	PENN-0708	7480	
7:	590	06/03/2003				
Jane Massey Licata				EXAMINER		
66 E Main Street Marlton, NJ 08053				TUNG,	TUNG, JOYCE	
				ART UNIT	PAPER NUMBER	
	·			1637	19	
				DATE MAILED: 06/03/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

Applicant(s)

09/624,946

Examiner

Joyce Tung

Art Unit 1637

Greene et al.



	The MAILING DATE of this communication appears	on the cover sheet with the corres	pondence address
	for Reply		
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.136 (a). In		
mailing - If the p - If NO p - Failure - Any re	ions of time may be available under the provisions of 37 CFR 1.136 (a). In a plate of this communication, beeriod for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	ne statutory minimum of thirty (30) days will be and will expire SIX (6) MONTHS from the mailin he application to become ABANDONED (35 U.S	e considered timely. ng dete of this communication. S.C. § 133).
Status			
1) 💢	Responsive to communication(s) filed on Mar 6, 20	003	<u> </u>
2a) 🗌	This action is FINAL . 2b) X This act	tion is non-final.	
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under Ex pa		
Disposi	tion of Claims		
4) 💢	Claim(s) <u>5-11</u>	is/are	e pending in the application.
4	la) Of the above, claim(s)	is/ar	e withdrawn from consideration.
5) 🗆	Claim(s)		is/are allowed.
6) 💢	Claim(s) <u>5-11</u>		is/are rejected.
7) 🗆	Claim(s)		is/are objected to.
8) 🗆	Claims	are subject to restric	ction and/or election requirement.
Applica	ition Papers		
9) 🗌	The specification is objected to by the Examiner.		
10)	The drawing(s) filed on is/are	$(a) \square$ accepted or $(b)\square$ objects	ed to by the Examiner.
	Applicant may not request that any objection to the o	drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).
11) 🗆	The proposed drawing correction filed on	is: a)□ approved	b) \square disapproved by the Examiner.
	If approved, corrected drawings are required in reply	to this Office action.	
12)	The oath or declaration is objected to by the Exam	iner.	
Priority	under 35 U.S.C. §§ 119 and 120		
13) 🗌	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)	-(d) or (f).
a) [☐ All b)☐ Some* c)☐ None of:		
	1. \square Certified copies of the priority documents have	ve been received.	
	2. Certified copies of the priority documents have	ve been received in Application N	No
	3. Copies of the certified copies of the priority depolication from the International Bure	eau (PCT Rule 17.2(a)).	this National Stage
	ee the attached detailed Office action for a list of the		(0)
14) ∐ a) [Acknowledgement is made of a claim for domestic		
15) 🗌	The translation of the foreign language provisional Acknowledgement is made of a claim for domestic		
Attachm		. p	
	otice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper	No(s)
2) No	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application	
3) 🔲 Inf	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:	
3) 🔲 Int	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:	

Application/Control Number: 09/624,946

Art Unit: 1637

DETAILED ACTION

1. The amendment filed 3/6/2003 has been entered. Following the entry of the amendment, claims 5-11 are pending.

Rejections and/or objected from the previous office action are hereby withdrawn. The following rejections are either newly applied or reiterated. They constitute the complete set presently being applied to the instant application.

NEW GROUNDS OF REJECTIONS

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 5-11 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of copending Application No. 09/977,716 and claims 1, 11 and 13-14 of copending Application No. 09/783,896. Although

Application/Control Number: 09/624,946 Page 3

Art Unit: 1637

the conflicting claims are not identical, they are not patentably distinct from each other because the instant claim 1 of copending Application No. 09/977,716 and claims 1, 11 and 13-14 of copending Application No. 09/783,896 are drawn to a method for detecting molecules expressing a selected epitope in a sample involving immobilizing a molecule expressing a selected epitope to a selected surface, contacting the surface with an epitope detector which binds to the immobilized molecules and the epitope detector comprising an oligonucleotide attached to a monoclonal antibody, amplifying the oligonucleotide, staining the amplified oligonucleotides with fluorescent dye and measuring the fluorescence emitted from the stained oligonucleotide. The claims 5-11 of the instant invention are drawn to a system for quantifying molecules expressing a selected epitope comprising a selected surface on which a molecule expressing a selected epitope, an epitope detector consisting of a single chain Fv or a constrained epitope specific CDR for the epitope which is modified for the attachment of an oligonucleotide and the oligonucleotide attached to the single chain Fv or the constrained epitope specific CDR. Since the system of the instant invention comprises the components to fulfill the method of claim 1 of copending Application No. 09/977,716 and claims 1, 11 and 13-14 of copending Application No. 09/783,896. Therefore, these inventions are overlapping in scope. .

Thus this is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Application/Control Number: 09/624,946 Page 4

Art Unit: 1637

Claim Rejections - 35 USC § 112

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 5. Claims 5-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- a. Claims 5-7 are vague and indefinite because of the phrase "an oligonucleotide" in step (c). It is unclear whether the oligonucleotide of step (c) is referred to the oligonucleotide which is attached to the single chain Fv. Clarification is required.

In addition, the phrase "an aRNA technique" is unclear because it can not be determined whether the aRNA technique is the same as the immuno- aRNA technique used in the method of Eberwine et al. (5922,553, issued 7/14/1999)). Clarification is required.

CONCLUSION

- 6. Claims 5-11 is/are rejected and/or objected to for the reason(s) set forth above.
- 7. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

Application/Control Number: 09/624,946 Page 5

Art Unit: 1637

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

8. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung

May 21, 2003

ETHAN WHISENANT